Taken together, NCL is closely associated with drug resistance, so NCL inhibitor or the combination of NCL and MDR1 inhibitors may provide a potential therapeutic option for the treatment of multipdrug resistance in cervical cancer. The gene discussed is NUCLEOLIN; the disease is cervical cancer.